Text resize: A A A

milestones

2000 | 2001 | 2002 | 2003 | 2005| 2006| 2007| 2008| 2009

Dr. Reddy’s has always been committed to creating value by applying science to help people lead healthier lives – Reditux™ is yet another example of this commitment. This is a proud moment for the organization. We have succeeded in developing this very complex molecule which will help in providing an affordable solution to patients.

Dr. K. Anji Reddy
Founder Chairman, Dr.Reddy's

Launches Reditux™ (Rituximab) – the world’s first biosimilar of a monoclonal antibody

Dr. Reddy’s Launches Reditux™, our brand of rituximab, a monoclonal antibody (MAb) used in the treatment of Non-Hodgkin’s Lymphoma. Reditux™ is the world’s first monoclonal antibody (MAb) biosimilar. The launch event was held in Hyderabad on 27th April 2007 with over 100 leading oncologists from the country attending event.

Click to read related memories

Becomes No.1 pharmaceutical company in India in turnover and profitability

On the back of a stellar performance, Dr. Reddy’s finishes the financial year with revenues of USD 1.5 billion and becomes the number one pharmaceutical company in India in turnover and profitability.

Click to read related memories

Balaglitazone (DRF 2593) enters Phase III of clinical trials

Dr. Reddy’s and Rheoscience commence the first Phase III clinical trial of Balaglitazone (DRF 2593), a novel TZD candidate for the treatment of diabetes mellitus. The study is the first in a series of planned Phase III trials which will investigate the safety and efficacy of Balaglitazone, as an oral anti-diabetic drug. Balaglitazone becomes the most advanced NCE from India.

Click to read related memories

2007

Reditux™ – the world’s first monoclonal antibody biosimilar